More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A new experimental study focused on how different sex hormones can affect the heart's ability to properly pump blood. Estradiol, the most active form of estrogen, stood out as a hormone that requires additional research.
Electromyometrial imaging creates 3D maps of contractions during labor in real-time, which can help clinicians track contraction patterns and make decisions regarding patient management.
Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought.
Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.
New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.
